Directed evolution using yeast display was employed to isolate novel NKp30 variants that bind to B7H6 with higher affinity compared to the native receptor but retain its fast association and dissociation profile. Two variants, CC3 and CC5, were expressed as soluble Fc-fusion proteins and CARs containing CD28 and CD3? intracellular domains. These Fc fusion protein forms of NKp30 and its variants were better able to bind tumor cells expressing low levels of B7H6 than TZ47, and exhibited improved in vitro tumor cell killing relative to NKp30. Also, CAR T cells expressing the engineered variants produced unique cytokine signatures in response to multiple tumor types expressing B7H6 compared to both NKp30 and TZ47. These findings suggest that natural CAR receptors can be fine-tuned to produce more desirable signaling outputs while maintaining evolutionary advantages in ligand recognition relative to scFvs.

The present disclosure provides compositions of genetically modified cells that are hypoimmunogenic. The present disclosure also provides methods of making hypoimmunogenic cells and using hypoimmunogenic cells for the treatment of cancer and autoimmune conditions.

A method efficiently produces cytotoxic T lymphocytes having intrinsic properties of lymphocytes of the acquired immune system suitable for cellular immunotherapy. The method includes culturing CD4/CD8 double-positive T cells in a medium containing IL-7 and a T-cell receptor activator, to induce CD8?.sup.+?.sup.+ cytotoxic T lymphocytes.

Provided herein are acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.

The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

The disclosure relates to antigen binding domains that specifically bind to a major histocompatibility class I (MHC I) complex comprising an a chain encoded by HLA-A*11 alleles. The disclosure further relates to antibodies and receptors comprising said antigen binding domains, and their use in diagnostics and adoptive cell therapy.

A cancer treatment composition and a cancer treatment method. Provided are a cancer treatment method and a treatment composition for patients for whom an anti-PD-1 antibody or anti-PD-L1 antibody treatment has failed.

The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-CD4 CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.

The present disclosure relates to a method of diagnosing or treating myeloid disorders and acute leukemias by using a tumor specific antigen selected from CD63, CD151, CD72, CD84, CD69, and CD109. Further provided are an antigen binding protein (ABP), an ABP-drug conjugate, and a CAR targeting the tumor specific antigen, and methods for their use.

The present invention provides a chimeric antigen receptor (CAR) that recognizes B7-H3 (CD276), as well as methods of use in the treatment of diseases and disorders.